CROM, a full-service contract research organisation (CRO) based in Verona, Italy, has established a new company, CROMSOURCE, after acquiring Belgian counterpart MSOURCE for an undisclosed sum.
According to its owners, CROMSOURCE will offer “complete international coverage and a full range of clinical research services and staffing solutions”. It will have a staff of around 400 employees and revenues of more than €50 million.
The new company will be headed by chief executive officer (CEO) Dr Oriana Zerbini, the founder and owner of CROM. Frank van de Wijngaert, the former CEO of MSOURCE, will leave CROMSOURCE on 15 May.
With headquarters close to Brussels, MSOURCE is a medium-sized CRO specialising in staffing solutions and medical device trials.
Active since 1994 and part of the German TÜV SÜD Group of companies since 2008, it has covered the European market through affiliates in the UK, Netherlands, Germany, Spain and Poland, as well as extending its services to the US through partnership.
“After the excellent performance and the dramatic growth achieved in the last years, this acquisition is a further fundamental step in the CROM strategy to strengthen its position at an international level,” CROMSOURCE said.
The new company will bring together the capabilities and expertise of MSOURCE and CROM while building on CROM’s well-established infrastructure, it noted. In particular, MSOURCE will complement the CROM clinical research service portfolio by adding its clinical resourcing experience to the mix.
“Over recent years, the required complexity of drug and medical device development has increased, meaning that a full range of innovative and flexible development approaches are now necessary for success,” CROMSOURCE pointed out
